Table 4.
Properties of Direct-acting Oral Anticoagulants*
| Characteristic | Dabigatran | Rivaroxaban | Apixaban | Edoxaban |
|---|---|---|---|---|
| Target | Factor IIa | Factor Xa | Factor Xa | Factor Xa |
| Prodrug | Yes | No | No | No |
| Dosing | BID | OD | BID | OD |
| Bioavailability | 6.5% | 80–100%* | 50% | 62% |
| Half-life | 12–14 h | 5–13 h | 8–15 h | 10–14 h |
| Renal clearance | 85% | ~33% | ~27% | ~50% |
| Cmax | 1–2 h | 2–4 h | 3–4 h | 1–2 h |
| Interactions | P-gp inhibitors | Strong inhibitors of CYP3A4 and P-gp | Strong inhibitors of CYP3A4 and P-gp | P-gp inhibitors |
OD: once daily; BID: twice daily; CYP3A4: intestinal cytochrome P450 3A4; Cmax: time to maximal blood concentration; P-gp: P-glycoprotein
*
In order of appearance on the market.